Bigfoot Biomedical: Reimagining Diabetes Care with a Novel AP System

article image

Bigfoot Biomedical is working to develop an artificial pancreas (AP) system that combines best-in-class devices and algorithms on a secure, highly connected, and highly automated platform, making it the first truly patient-, physician- and payor-friendly AP.

With FDA’s earlier-than-expected approval last month of Medtronic plc’s 670G hybrid (treat-to-range) closed-loop insulin delivery system, the artificial pancreas (AP) concept—not so long ago, just a futuristic idea—has taken a huge step forward (see Sidebar, “ Medtronic and Abbott Score Important FDA Approvals in Diabetes Device Space).


This article is restricted to subscribers only.

Sign in to continue reading.


We're here to help! Please contact us at: